middle.news
Medical Developments Reports Strong Q2 FY25 Cash Flow and Revenue Growth
6:39pm on Sunday 1st of June, 2025 AEST
•
Healthcare
Read Story
Medical Developments Reports Strong Q2 FY25 Cash Flow and Revenue Growth
6:39pm on Sunday 1st of June, 2025 AEST
Key Points
Q2 FY25 revenue rises to $10.9 million, up $1.8 million from previous quarter
Operating cash flow improves by $4.6 million to $1.9 million in Q2 FY25
Cash balance stands at $17.6 million as of 31 December 2024
Penthrox sales grow strongly in Australian hospitals and European markets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Medical Developments International (ASX:MVP)
OPEN ARTICLE